Sana Biotechnology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
SANA$2.37+1.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(unaudited)
(in thousands, except per share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $83,800 | $71,870 |
| Marketable securities | 17,336 | 66,512 |
| Restricted cash | 4,195 | 4,195 |
| Prepaid expenses and other current assets | 6,359 | 6,099 |
| Total current assets | 111,690 | 148,676 |
| Property and equipment, net | 25,673 | 26,906 |
| Operating lease right-of-use assets | 35,845 | 38,313 |
| Intangible asset | 59,195 | 59,195 |
| Goodwill | 140,627 | 140,627 |
| Other non-current assets | 563 | 3,173 |
| TOTAL ASSETS | $373,593 | $416,890 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,123 | $1,669 |
| Accrued compensation | 7,584 | 13,240 |
| Accrued expenses and other current liabilities | 8,124 | 8,679 |
| Operating lease liabilities | 14,878 | 14,938 |
| Contingent consideration | 53,556 | 40,200 |
| Total current liabilities | 86,265 | 78,726 |
| Operating lease liabilities, net of current portion | 60,450 | 63,924 |
| Contingent consideration, net of current portion | 80,907 | 83,518 |
| Success payment liabilities | 16,926 | 19,238 |
| Other non-current liabilities | 9,805 | 10,600 |
| Total liabilities | 254,353 | 256,006 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - |
| Common stock, $0.0001 par value; 750,000 shares authorized; 269,817 and 266,732 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 27 | 27 |
| Additional paid-in capital | 2,015,441 | 2,009,845 |
| Accumulated other comprehensive income (loss) | (2) | 28 |
| Accumulated deficit | (1,896,226) | (1,849,016) |
| Total stockholders' equity | 119,240 | 160,884 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $373,593 | $416,890 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.